Time filter

Source Type

Li Y.,Changchun Institute of Technology | Miao Z.,Jilin University | Wang B.,Jilin Province Tumor Hospital
Proceedings of 2013 3rd International Conference on Computer Science and Network Technology, ICCSNT 2013 | Year: 2014

An adapt Active Appearance Model (AAM) which can initialize the contour automatically is proposed to segment lung CT images with pathologies. Current segmentation methods have failed because the traditional PCA is not suitable to handle outliers caused by update points of pathology area. A fast robust PCA is cited to design the active AAM which can effectively segment the pathology lungs. For the same 30-cases from Jilin Province Tumor Hospital, two other schemes and algorithm in the paper are compared. The experiment results confirm feasibility of the active AAM which achieved a 93.9% overall sensitivity per section. © 2013 IEEE.

Liu D.,No. 208 Hospital of China PLA | Yang S.-Q.,Jilin University | Zhang J.,Jilin Province Tumor Hospital
Chinese Journal of Cancer Prevention and Treatment | Year: 2014

OBJECTIVE: To discuss the diagnosis value of CEUS in primary liver carcinoma. METHODS: Thirty-one cases of primary liver cancer patients were selected during 2010-03-2012-03 in the No. 208 hospital of China PLA, and their clinical data and CEUS examination were retrospectively analyzed. RESULTS: Totally 22(78.6%) of HCC were "fast-in and fast-out", which was much obviously observed in poorly differentiated cases. The enhancement pattern presented "fast-in and fast-out"; Three (100.0%) of ICC were "fast-in and fast-out". Rim-like hyperechoic enhancement in the arterial phase was found with net-shaped hyperechoic enhancement interior or without centripetal filling in. Hypoechoic enhancement was observed in portal phase. The sensitivities of conventional ultrasound and CEUS were 72.4% and 93.5%, and there was a statistically difference (χ2=6.125, P=0.013). CONCLUSION: CEUS dynamic model of primary liver carcinoma has significant characteristics, contrast-enhanced ultrasound can increase the diagnostic rate of primary liver cancer.

Wang Q.,Northeast Dianli University | Wang B.,Jilin Province Tumor Hospital
ICIC Express Letters | Year: 2013

To improve the poor performance of current computer-aided diagnosis (CAD) in lung CT images caused by irregular nodules, new detection scheme based on manifold learning with latent variable is proposed. Testing dataset used in this study consisted of CT scans from 100 different patients in our Hospital. Characteristics of most nodules in these scans were irregular. These nodules have caused seriously false recognition by both current CAD and radiologists. Relative position from the suspected nodule to the centre of the whole lung area is added as a new feature to traditional shape and texture features to optimize Support Vector Machine (SVM). Four CAD schemes were investigated for the same 100 irregular samples. Our scheme achieved a 93.7% overall sensitivity with 1.83% False Positives (FPs) per section, which was in general superior compared with the other three CAD schemes for our application. © 2013 ICIC International.

Zhou Q.,Guangdong General Hospital and Guangdong Academy of Medical science | Zhou C.-C.,Shanghai Pulmonary Hospital | Chen G.-Y.,Haerbin Medical University Affiliated Tumor Hospital | Cheng Y.,Jilin Province Tumor Hospital | And 9 more authors.
Lung Cancer | Year: 2014

Objectives: Aim of the study was to investigate efficacy and safety of sorafenib in patients with advanced lung adenocarcinoma after failure of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) therapy. Patients and methods: Patients who were diagnosed with stage IIIB or stage IV lung adenocarcinoma, and benefited from one prior EGFR-TKI therapy and then failed, were eligible. No more than one previous chemotherapy regimen was permitted. Patients received oral sorafenib 400. mg twice daily continuously until disease progression or intolerable toxicity. Primary endpoint was disease control rate (DCR). Secondary endpoints included safety, progression-free survival (PFS) and overall survival (OS). For patients who agreed to provide peripheral blood or tumor tissue, we analyzed the genotype of Bcl-2-interacting mediator of cell death (BIM) deletion polymorphism and EGFR mutation status. Results: Of 65 enrolled patients, 64 were evaluable. The DCR was 32.8%, which did not meet the predefined statistical hypothesis of 38.4%. The median PFS and OS were 3.7 months [95% (confidence interval), 3.5-3.9 months] and 7.4 months (95% CI, 5.7-9.2 months), respectively. Logistic regression analysis showed no correlation between DCR and age, gender, smoking status and performance status. Hand-foot syndrome (HFS) was the predominant toxicity occurring in 71.9% of patients. Fourteen patients (21.9%) had ≥grade 2 dermatologic reactions that resulted sorafenib dose reduction in three patients (4.7%). Of 36 patients, the BIM deletion polymorphism was found in 3, and no response to sorafenib was observed. In 30 tumor tissues, 22 EGFR active mutations were found. The DCR had no significant difference between mutation-positive and wild-type patients (31.8% vs. 42.9%, respectively; HR, 0.622; p= 0.665). Conclusion: Sorafenib monotherapy did not achieve positive result in patients defined in our trial and we need better biomarker to determine the population who can benefit from sorafenib treatment (ClinicalTrials.gov number: NCT00922584). © 2014 Elsevier Ireland Ltd.

Wu D.,Jilin University | Shi W.,Beijing Institute of Pharmacology and Toxicology | Zhao J.,Jilin University | Wei Z.,Jilin University | And 6 more authors.
Archives of Biochemistry and Biophysics | Year: 2016

CPT-11 (irinotecan) is a derivative of camptothecin which is a natural product derived from the Chinese tree Camptotheca acuminta and widely used in antitumor therapy. Here, the in vitro anti-tumor activity and associated mechanisms of a novel derivative of camptothecin, ZBH-1205, were investigated in a panel of 9 human tumor cell lines, as well as in HEK 293 and SK-OV-3/DPP, a multi-drug resistant (MDR) cell line, and compared to CPT-11 and 7-ethyl-10-hydroxy-camptothecin (SN38). Comparisons between the different compounds were made on the basis of IC50 values as determined by the MTT assay, and flow cytometry was used to evaluate cell cycle progression, apoptosis, and the levels of pro- and active caspase-3 among different treatment groups. Interaction between the molecules and topoisomerase-1 (Topo-1)-DNA complexes was detected by a DNA relaxation assay. Our results demonstrated that IC50 values for ZBH-1205 ranged from 0.0009 μmol/L to 2.5671 μmol/L, which were consistently lower than IC50 values of CPT-11 or SN38 in the panel of cell lines, including SK-OV-3/DPP. Furthermore, ZBH-1205 was more effective than CPT-11 or SN38 at stabilizing Topo-1-DNA complexes and inducing tumor cell apoptosis. Therefore, ZBH-1205 is a promising chemotherapeutic agent to be further assessed in large-scale clinical trials. © 2016 Elsevier Inc.

Discover hidden collaborations